ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > ProMIS making progress, don't believe the hate

<< Previous

Bullboard Posts

Next >>

Comment by farmerjaneon Apr 13, 2021 9:46pm

289 Views

Post# 32990504

RE:ProMIS making progress, don't believe the hate

Elliot, really look at your blog mostly about PP's and future with LeBron James. Who cares tell him to keep playing basket ball. Nothing about Partnerships, Collabarations actual science deals?
Another smoke screen by you and Eugene, and thank-you for the naysayer and troll comment as i am going to double down and expose much more of you and Eugene and your PP's. One last thing tell your buddy with the phony serology test to get there web page straight as they have different dates for requistion forms for samples being sent and tested Oct 15,2020 and Mar 30,2021. Was this eningeered by you?

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!